Maven Clinic vs Becton Dickinson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Maven Clinic is the largest virtual clinic for women and families, providing care across fertility, maternity, menopause, and pediatrics through employer and health plan benefits.
About
Maven Clinic is a digital health company founded in 2014 by Kate Ryder that has grown into the largest virtual care platform dedicated to women and family health, raising over $300M at a $1.35B valuation. The company provides a comprehensive virtual clinic covering fertility, maternity, menopause, family planning, pediatric care, and general women's health through a network of OB-GYNs, midwives, reproductive endocrinologists, nutritionists, mental health specialists, and other providers. Maven distributes primarily through employer health benefits programs and health plan partnerships, serving over 30 million covered lives through partnerships with large employers and insurers. The platform has demonstrated significant return on investment for employers through reduced NICU costs, lower preterm birth rates, and improved fertility treatment outcomes. Maven has expanded internationally to serve global employers managing diverse populations across multiple countries. The company competes with Progyny in fertility benefits and with Hims & Hers and other women's health platforms in the direct-to-consumer market while maintaining the broadest clinical scope of any women's and family health platform.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
About
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.